NCT07510386

CGM After Discharge From Hospital

Continuous Glucose Monitoring for Post-discharge Diabetes Management

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 64 (estimated)
• Sponsor: Icahn School of Medicine at Mount Sinai · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an investigator initiated prospective, randomized controlled trial which aims to compare two groups of patients with either type 2 or steroid-induced diabetes who are discharged with insulin. The intervention group will use the Libre 3 Plus continuous glucose monitoring (CGM) system at discharge, while the control group will use blinded CGM and fingerstick monitoring. Both the intervention and control groups will wear the sensor for 28 days post discharge and participate in telehealth diabetes management visits. The target enrollment for the study is 65 participants and participants are expected to be in the study for up to 35 days.

Conditions

• Type 2 Diabetes
• Steroid-induced Diabetes

Interventions

Type	Name	Description
DEVICE	Libre 3 Plus continuous glucose monitoring (CGM) system	Use of unmasked CGM after discharge
DEVICE	Blinded Continuous Glucose Monitoring	Masked CGM
BEHAVIORAL	Finger stick	Self-monitoring blood glucose

Timeline

• Start date: 2026-04-01
• Primary completion: 2026-10-01
• Completion: 2026-11-01
• First posted: 2026-04-03
• Last updated: 2026-04-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study